1. Home
  2. EXTR vs MIRM Comparison

EXTR vs MIRM Comparison

Compare EXTR & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Extreme Networks Inc.

EXTR

Extreme Networks Inc.

SELL

Current Price

$26.06

Market Cap

3.0B

ML Signal

SELL

Logo Mirum Pharmaceuticals Inc.

MIRM

Mirum Pharmaceuticals Inc.

SELL

Current Price

$92.44

Market Cap

7.2B

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
EXTR
MIRM
Founded
1996
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Telecommunications Equipment
Biotechnology: Pharmaceutical Preparations
Sector
Telecommunications
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.0B
7.2B
IPO Year
1999
2019

Fundamental Metrics

Financial Performance
Metric
EXTR
MIRM
Price
$26.06
$92.44
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
8
12
Target Price
$33.63
★ $157.71
AVG Volume (30 Days)
★ 1.8M
559.1K
Earning Date
10-28-2026
11-03-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 616.67
74.59
EPS
★ 0.12
N/A
Revenue
★ $1,283,593,000.00
$19,138,000.00
Revenue This Year
$9.74
$37.65
Revenue Next Year
$9.69
$21.04
P/E Ratio
$223.67
★ N/A
Revenue Growth
★ 12.59
N/A
52 Week Low
$13.48
$63.23
52 Week High
$33.73
$130.00

Technical Indicators

Market Signals
Indicator
EXTR
MIRM
Relative Strength Index (RSI) 60.86 56.52
Support Level $21.33 $87.38
Resistance Level $33.08 $98.34
Average True Range (ATR) 1.52 4.15
MACD 0.42 0.73
Stochastic Oscillator 83.95 60.16

Price Performance

Historical Comparison
EXTR
MIRM

About EXTR Extreme Networks Inc.

Extreme Networks Inc is an AI-powered cloud-based networking company focused on delivering simple and secure solutions that enable connections among devices, applications, and users. The Company leverages artificial intelligence, analytics, and automation in its products and services, and designs, develops, and manufactures wired, wireless, and software-defined wide area network (SD-WAN) infrastructure equipment. Its offerings include networking equipment, software subscriptions, related maintenance contracts and the Extreme Platform ONE solution. The Company operates in a single reportable segment focused on the development, marketing, and sale of network infrastructure equipment and related software and subscriptions. The Company generates maximum revenue from the United States.

About MIRM Mirum Pharmaceuticals Inc.

Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.

Share on Social Networks: